Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.39 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | FURIN | P09958 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30354595 | 0.95 | MME (0.40) | MMEPDCD1LG2CD274CA2CA1 | |
| SCHEMBL30122865 | 0.94 | MME (0.42) | MMEPDCD1LG2CD274CA2CA1 | |
| SCHEMBL31265320 | 0.89 | NPSR1 (0.38) | MMENPSR1 | |
| SCHEMBL30123046 | 0.89 | MME (0.41) | MME | |
| SCHEMBL30353283 | 0.87 | NPSR1 (0.41) | MMEPDCD1LG2CD274CA2CA1 | |
| SCHEMBL3396685 | 0.87 | NPSR1 (0.41) | MMEPDCD1LG2CD274CA2CA1 | |
| SCHEMBL3396676 | 0.87 | NPSR1 (0.41) | MMEPDCD1LG2CD274CA2CA1 | |
| SCHEMBL31064974 | 0.87 | NPSR1 (0.44) | MMENPSR1 | |
| SCHEMBL11106438 | 0.87 | CA2 (0.41) | MMEPDCD1LG2CD274CA2CA1 | |
| SCHEMBL31174306 | 0.87 | CA2 (0.41) | MMEPDCD1LG2CD274CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4074729-B1 | AMYLIN ANALOGUES | ZEALAND PHARMA AS (DK) | 2026-04-15 | — | — | EP | claimed |
| US-11382956-B2 | Amylin analogues | ZEALAND PHARMA A/S (DK) | 2022-07-12 | — | — | US | claimed |
| EP-4736946-A2 | AMYLIN ANALOGUES | Zealand Pharma A/S (DK) | 2026-05-06 | — | — | EP | disclosed |
| EP-4736945-A2 | AMYLIN ANALOGUES | Zealand Pharma A/S (DK) | 2026-05-06 | — | — | EP | disclosed |
| EP-4074729-B1 | AMYLIN ANALOGUES | ZEALAND PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| US-20250064895-A1 | AMYLIN ANALOGUES | ZEALAND PHARMA A/S (DK) | 2025-02-27 | — | — | US | disclosed |
| US-12083164-B2 | Amylin analogues | ZEALAND PHARMA A/S (DK) | 2024-09-10 | — | — | US | disclosed |
| CN-109863168-B | Amylin analogs | 西兰制药公司 | 2023-04-18 | — | — | CN | disclosed |
| EP-4144362-A1 | COMPOSITIONS COMPRISING SHORT-ACTING HORMONES FOR TREATING OR PREVENTING OBESITY AND PUMPS COMPRISING SAID COMPOSITION | Adocia (FR) | 2023-03-08 | — | — | EP | disclosed |
| EP-4129324-A1 | COMPOSITIONS COMPRISING AT LEAST AN AMYLIN RECEPTOR AGONIST AND A GLP-1 RECEPTOR AGONIST | Adocia (FR) | 2023-02-08 | — | — | EP | disclosed |
| US-11382956-B2 | Amylin analogues | ZEALAND PHARMA A/S (DK) | 2022-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12083164-B2 | Amylin analogues | IAPP, GLP1R, AMY2A | MME 78/4885PDCD1LG2 4094/4885CD274 4415/4885 |
| US-20250064895-A1 | AMYLIN ANALOGUES | IAPP, GLP1R, AMY2A | MME 78/4885PDCD1LG2 4094/4885CD274 4415/4885 |
| US-11382956-B2 | Amylin analogues | IAPP, GLP1R, AMY2A | MME 78/4885PDCD1LG2 4094/4885CD274 4415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.